Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Dr_Dan  – 2020-02-11 16:20 (295 d 22:37 ago) – Posting: # 21159
Views: 1,049

Dear qualityassurance
In case of a bioequivalence study, it also depends on whether the concomitant medication was
given obligatory to all subjects or was taken accidentally by one or maybe more subjects. In the first case, the effect for the test and the reference formulation would be the same and you do not need to argue. Otherwise, a detailed risk analysis should be carried out, which describes the estimated PK effects of the concomitant medication on the bioequivalence decision. If only a view subjects are affected a sensitivity analysis could be carried out.
I hope this helps.

Kind regards and have a nice day

Complete thread:

 Admin contact
21,234 posts in 4,428 threads, 1,484 registered users;
online 4 (1 registered, 3 guests [including 2 identified bots]).
Forum time: Thursday 14:57 CET (Europe/Vienna)

Every man is fully satisfied that there is such a thing as truth,
or he would not ask any question.    Charles Sanders Peirce

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz